CRV returns to profit after difficult years

Net sales of CRV and its subsidiaries increased by more than
€10 million to over €195 million – the highest figure in three years. Operating profit improved by approximately €8 million to €3,8 million. Despite a substantial tax payment, a positive net profit of €700.000 was also achieved. Previous years were less favorable. Internal guidelines dictate that no member benefits (dividends/post-payments) will be distributed this year.

In its previously outlined reorganization plan, CRV anticipated a smaller livestock population in the Netherlands and Flanders. This allowed the company to achieve significant cost savings, but "the expected reduction in livestock numbers failed to materialize last year, and milk and meat prices remained strong." As a result, CRV's revenue exceeded expectations, partly due to increased sales of SiryX semen.

The bluetongue outbreak in the summer of 2024 also led to increased inseminations, but CRV and its members were unhappy about this. "The virus caused a lot of hardship to our member farmers. More inseminations were also needed to get cows pregnant," said CFO Egon Verheijden when the figures were announced.

CRV's international subsidiaries performed as expected last fiscal year. Results in Germany and the Czech Republic remained stable, and in New Zealand, the company achieved revenue growth of approximately 8%. The Brazilian subsidiary also posted a favorable result this year. This has not always been the case. CRV USA achieved revenue growth last year, but cost control remains a key focus. Because China closed its borders to foreign genetics, this market disappeared for CRV.

In the first months of the 2025/26 fiscal year, turnover remained stable. Despite declining milk prices and rising manure disposal costs, CRV expects turnover for the entire fiscal year to exceed the target.